As the chair at the helm of Biocon changes face, there is a new zeal to increase the efforts in making the processes more robust and to make them free from excessive human interference. The company is embarking on a digital journey from the quality control and process control point of view, which according to the new Managing Director Mr. Siddhartha Mittal is the next step ahead to make sure that the company in the competitive Indian drug market is above the floatation lines.
The idea to digitize was pre-existent and dedicated teams have also been set up to pursue the same and in hindsight if the global drug scenario is taken into picture the need had already arisen with the CDC’s clear directive and the rest of the countries following on that notion for digitization in the fields of quality management and the pre-process compliance.
The industry has had a major impact of the Goods Manufacturing Practices (GMP) regulations brought in by the government, but the drug approval stays relatively similar and given the track record of GMP compliance of Biocon it is safe to think that the company isn’t suffering in that dimension of creation of drugs.
The US is one of the major markets for the R&D for drug companies in today’s times and as the competition in the market grows following equity pricing of drugs under the governments directive the main focus has been implanted on making the production processes robust in order to mitigate any challenges that the company might face in the future.
Tags : Biocon's, Goods Manufacturing Practices, drug companies,